Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach Publication Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach CertaraSeptember 15, 2017
Agreeing to Submission Document Timelines & Sticking to Them: Fairy Tale or Reality? On-Demand Webinar Agreeing to Submission Document Timelines & Sticking to Them: Fairy Tale or Reality? In this webinar, Steve Sibley defined best practices for establishing submission timelines that won’t change,…CertaraSeptember 14, 2017
Medical Writing Competency Model—Section 2: Knowledge, Skills, Abilities, and Behaviors Publication Medical Writing Competency Model—Section 2: Knowledge, Skills, Abilities, and Behaviors CertaraAugust 30, 2017
Medical Writing Competency Model—Section 1: Functions, Tasks, and Activities Publication Medical Writing Competency Model—Section 1: Functions, Tasks, and Activities CertaraAugust 30, 2017
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal White Paper Drug Asset Evaluation: Increasing “Probability of Success” of a Deal Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…CertaraAugust 24, 2017
Investigational Drug Gap Analysis Brochure Investigational Drug Gap Analysis As the process of drug development has increased in cost and complexity, Certara has developed…CertaraAugust 14, 2017
Clinical Pharmacology—The Quarterback of Drug Development Press Coverage Clinical Pharmacology—The Quarterback of Drug Development Clinical pharmacology accounts for about 50% of a drug label. Its scope ranges from facilitating…CertaraAugust 14, 2017
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Publication Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types CertaraAugust 1, 2017
Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Publication Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients CertaraJuly 15, 2017
Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics Publication Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics CertaraJuly 1, 2017